Blackrock Neurotech MoveAgain trial expands to third clinical site
The trial evaluates the companys neural interface system in assisting paralyzed patients with daily tasks; the new site is expected to accelerate enrollment.
Blackrock Neurotech
2 entries6 月 2026
Blackrock Neurotech high-density array receives FDA Breakthrough designation
The Breakthrough Device designation is expected to accelerate FDA review of the next-generation recording array intended for multiple indications.